drugset / Trial / NCT05275504
Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a first-in-human (FIH), multicenter, open-label Phase I dose escalation study to evaluate the safety and preliminary efficacy of the TT-01488 tablet, a non-covalent reversible BTK inhibitor, for the treatment of adult patients with B-cell malignancies.
Timeline
- Start
- 2022-06
- Primary completion
- 2022-09
- Completion
- 2023-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TT-01488 | Unknown | 50 mg | Oral |